Newsletter Signup | Join Community | Cancer Types
The checkpoint inhibitor Tecentiq (atezolizumab) improves the outcomes of treatment for bladder cancer.
Vicinium promising for treatment of early stage and superficial bladder cancers.
Everywhere we look in the media, we find claims that different diets can improve our quality of life.
Stay Current With Bladder Cancer Treatment Advances & Connect with Others
FDA Approves PD-1 Checkpoint Inhibitor Opdivo for Treatment of Bladder Cancer
Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer
IDO inhibitor epacadostat and the anti-PD-1 drug Keytruda (pembrolizumab) promising in bladder cancer.
Study reports that ~ 60% of patients with advanced bladder cancer respond to Votrient/Taxol chemotherapy
Doctors from MD Anderson report results of Balversa in advanced Urothelial cancer - Now FDA Approved
U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer
Intravesical Taxotere® Effective in Recurrent Superficial Bladder Cancer
Study from Sloan Kettering: Robot-assisted laparoscopic cystectomy takes longer to complete but has less blood loss
Taxotere® and Gemzar® is Effective for Treatment of Advanced Bladder Cancer
More Evidence that Diabetes Drugs Increase Risk of Bladder Cancer
Some individuals are more genetically susceptible to this risk.
Hair Dye Linked to Bladder Cancer
Multi-Drug Chemo and Radiation Combo May Prolong Survival Time for Persons with Small-Cell Bladder Cancer
Radiation for Uterine Cancer May Increase Risk of Bladder Cancer
Death rate from bladder cancer continues to rise 20 years after exposure to high levels of arsenic in drinking water.
Learning about this often-overlooked cancer may save your life.
A Large Study Helps Define Outcomes for Patients with Superficial Bladder Cancer.